Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD4547 + Sapanisertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD4547 | AZD-4547 | FGFR1 Inhibitor 24 FGFR2 Inhibitor 18 FGFR3 Inhibitor 13 | AZD4547 selectively binds and inhibits FGFR1, 2, and 3, which may result in the inhibition of FGFR-mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22369928, PMID: 30115694, PMID: 32463741), and has demonstrated inhibitory effects on NTRK signaling (PMID: 34790577). | |
Sapanisertib | INK128|INK-128|TAK-228|MLN0128|MLN-0128 | mTOR Inhibitor 51 | Sapanisertib (MLN0128) is an ATP-competitive mTOR kinase inhibitor that induces apoptosis and inhibits growth in tumor cells (PMID: 25519700, PMID: 32488989). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 - SHTN1 FGFR2 E565A | Advanced Solid Tumor | sensitive | AZD4547 + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531). | 31911531 |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | AZD4547 + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531). | 31911531 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|